Alira Health's Approach to Market Access
A FIRST-CLASS STRATEGY HIGHLIGHTS AND DEMONSTRATES A DRUG'S SOURCES OF VALUE
A FIRST-CLASS STRATEGY HIGHLIGHTS AND DEMONSTRATES A DRUG'S SOURCES OF VALUE
Alira Health at Biovision 17 APRIL 4 - 6 | LYON, FRANCE
Alira Health at BIO-Europe Spring 17 A World of Opportunity MARCH 20 - 22 | BARCELONA, SPAIN
Welcome David Uffer! Alira Health is pleased to announce that David Uffer has joined the firm as a Partner, bringing his extensive expertise in business strategy, transaction services, and strategy execution to Alira Health’s clients worldwide.
High-sensitive troponin (hs-ctn) can accurately rule-out acute myocardial infarction (AMI) at early hours with high negative predictive value (NPV). However, low positive predictive value (PPV) causes false positives, leaving many patients under observation (46.9%-54%). Our novel technology demonstrates that a diagnostic algorithm of hs-ctn measured at two different clinically accepted cut-offs within the first 6 hours after emergency room presentation can accurately diagnose 99.3% of non-st segment elevation myocardial infarction (NSTEMI) patients and is highly cost-effective.
Michal Raciborski, Managing Director of Alira Health in Germany, will discuss how pharmaceutical asset deals can become a smart business development strategy for companies from Central and Eastern Europe during the Emerging Markets Forum in Berlin.
Alira Health acted as an M&A and financial advisor for Ipsen.
New name reflects dramatic expansion to include innovative research, product development, and business incubator
CMC Consulting Group (www.cmc-co.net) is pleased to announce its new name, Alira Health, effective January 1, 2017. The company’s decision reflects the continuing evolution of its advisory, consulting and research services in healthcare.
CMC Consulting Group, an international healthcare advisory firm, has announced its Medical Affairs Division’s (MAD) one-year anniversary. Since their October 2014 launch the MAD team has successfully served their client base in medical affairs research, clinical strategy, and advocacy by utilizing their extensive expertise in clinical sciences.
Mutuelle Nationale des Hospitaliers (MNH) acquired the majority stake in Groupe Profession Santé (GPS). The management of Groupe Profession Santé around Julien and Gérard Kouchner remains on board and minority shareholders.
Gabriele Brambilla, CEO of CMC Consulting Group, was the keynote speaker for the closing reception at the Harvard vs MIT Case Competition. In his speech, he gave a panoramic view on the US healthcare system in comparison with EU HC systems.
TCP Reliable purchased the assets of LaunchWorks Manufacturing Lab, an ISO 13485 certified contract manufacturing organization and provider of supply chain solutions. Prior to the transaction, LaunchWorks had been an operating unit of ArcherDX, Inc., a developer of NGS-based diagnostics based in Boulder, Colorado. LaunchWorks’ operations will remain at their current location in Beverly, Massachusetts.
CMC and EWMA held their first annual Wound Care Innovation Symposium on May 12th in Bremen, Germany. Among the presenting finalists, Imbed Biosciences Inc. was awarded the CMC-EWMA Innovation Award for their ultra-thin antimicrobial dressing. An estimated 50 people attended the symposium to discuss the latest cross-border and market expansion issues in the advanced wound care industry.
Recipharm AB today announces that it has entered into an agreement to acquire Italian CDMO, Mitim Srl for SEK 640 million. The transaction was completed on February 24, 2016 and adds scale and capabilities to the group. Mitim, located in Brescia, Italy, is currently owned by a private Italian family and is specialized in the filling of injectable beta lactam products.The acquisition of Mitim consolidates Recipharm’s leading position as a CDMO (Contract Development and Manufacturing Organization) and adds an important new technology with FDA inspected facilities. The transaction complements Recipharm’s existing Italian operations with a number of commercial and operational synergies and provides a substantial US presence.
Eukedos S.p.A. and Augens Capital announce the signature of a definitive agreement for Augeo 1 S.r.l., an investment vehicle affiliated with Augens Capital, to acquire Delta Med S.p.A. (“Delta Med”). The transaction is expected to close by the end of November.Delta Med is a leading global manufacturer of peripheral vascular access devices and is active in the production and distribution, in Italy and abroad, of disposable medical devices and accessories for infusion therapies, custom packs for operating rooms and other products for the pharmaceutical, healthcare and dental sectors.Based in Viadana, near Mantua in Northern Italy, Delta Med sells its products globally and generated revenues of €16.5 million in 2014.
CMC Consulting Group held its second M&A and Innovation in Healthcare Event in Brussels, at Cercle Royal Gaulois Artistique & Littéraire co-hosted with Johnson & Johnson Innovation Center and with IMD Business School Alumni in Belgium.
CMC congratulates its client, Keosys on the sale of a majority stake of the company to JMC Investment.Keosys takes a significant step forward thanks to the acquisition of a majority stake of the company by JMC Investment. Mr. Jérôme Fortineau, Founder & CEO of Keosys SAS will reinvest alongside JMC.Following sustained annual growth of 20% over the past 3 years, Keosys adds resources and leadership that will allow the company to extend the product offering and grow its international presence. Keosys’ goal is to become the world leader of imaging diagnosis and imaging management solutions for nuclear medicine.
Lavorel Groupe announced the acquisition of LTDAS Apotecnia through their subsidiary Lavorel Medicare S.A. Lavorel Medicare, which is 90% owned by Lavorel Groupe and 10% by Merieux Developpement, specializes in meeting the needs of the Health Care Market. Recently, Lavorel Medicare and Merieux Developpement have announced an additional acquisition of the minority stake in Israel's Ninox, a company that is developing an innovative solution in the treatment of sleep apnea.
CMC congratulates its client, Sidam S.r.l. on the sale of the company to Synopo S.p.A. Founded in 1991, Sidam manufactures highly innovative medical devices used in the contrast media delivery, infusion, special therapies and radioactive liquid preparation for major players in the medical device and biopharmaceutical sectors. CMC initiated the transaction with Synopo and acted as financial advisor to Sidam. "We strongly believe the partnership with Synopo will boost Sidam's growth in the coming years," commented Graziano Azzolini, founder of Sidam. "Their significant presence as a distributor in the Italian medical device market creates numerous operational and strategic synergies with Sidam." Added Annalisa Azzolini, new CEO of Sidam S.r.l., "I am thrilled to have Synopo as our new partner and look forward to working with them to realize our ambitious longer-term strategic objectives". "The operating leverage that is achievable through the combination of Synopo and Sidam was a key consideration behind this transaction," stated Carlo Bonomi, President and CEO of Synopo S.p.A. "Sidam is representative of Italian excellence in the medical device market globally and its expertise in R&D and manufacturing will help us become a major European player. We are delighted to join with the Azzolini family." Studio Legale Laghi Leo e Associati is the legal advisor for both Synopo and Sidam in the transaction.
CMC Transaction Services, the life science focused investment bank, congratulates its client, IDEX Corporation (based in Lake Forest, IL), on its acquisition of CiDRA Precision Services, LLC (CPS). Located in Wallingford, CT, CiDRA Precision Services is a leader in the design, manufacture and sale of microfluidic components serving the life science, health and industrial markets. CMC Transaction Services acted as financial advisor to IDEX Corporation.“The CMC team did a wonderful job in helping us both to identify CiDRA Precision Services and structure the transaction,” commented Gustavo Salem, President, IDEX Health & Science. “CMC developed deep insights into the market leading technology and product portfolio of CPS, and then used this knowledge to secure a successful deal.” “The CPS transaction underscores the value of CMC’s integrated advisory approach,” stated Benjamin Conway, managing director of CMC Transaction Services. “Combining strategy consulting with M&A advisory services enables us to construct and implement strategic initiatives in a seamless and efficient fashion. The inherent advantage of the approach is of meaningful benefit to clients such as IDEX Corporation.”
Johnston Blakely & Company, a CMC Group company, congratulates its client, CutisPharma, Inc., on its recapitalization and equity investment by Ampersand Capital Partners. Founded in 1998, CutisPharma develops and commercializes FIRST® unit-of-use prescription compounding kits to aid pharmacists in the preparation of compounded prescriptions. CutisPharma's rapidly expanding portfolio of kits is utilized in retail and hospital pharmacies across the United States.